Side effects can include nausea, constipation, diarrhea, osteoporosis, kidney damage, gallstones, and pancreatitis
Tesamorelin (Egrifta) is FDA-approved specifically to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy
Since the glucose-lowering effects of GIP have been shown to be impaired in patients with T2D, interest has focused on developing antidiabetic therapies based upon the actions of GLP-1 and GIP, the response to which remains intact
2023, December 14
Again, like, I said even if they already haven't really changed their calories, they just hit menopause
doi:10.2174/1570159x13666160502153022